These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30644585)

  • 61. Cangrelor in Percutaneous Coronary Intervention: Current Status and Perspectives.
    Alexopoulos D; Pappas C; Sfantou D; Lekakis J
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):13-22. PubMed ID: 29228817
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bridging with Tirofiban during Oral Antiplatelet Interruption: A Single-Center Case Series Analysis Including Patients on Hemodialysis.
    Walker EA; Dager WE
    Pharmacotherapy; 2017 Aug; 37(8):888-892. PubMed ID: 28543216
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The Use of Cangrelor as Bridge Antiplatelet Therapy in a Patient with Recent Percutaneous Coronary Intervention for Acute Coronary Syndrome, Who Developed Esophageal Perforation After Transesophageal Echocardiography.
    Guliyeva U; Karaüzüm K; Çam İ; İsrafilov R; Koç AF; Mirzamidinov D; Yılmaz H; Karaüzüm İ; Şahin T; Ural E
    Turk Kardiyol Dern Ars; 2024 Jul; 52(5):352-356. PubMed ID: 38982817
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors in vessels at low anatomic risk: a retrospective analysis of previously published data from the Basel Stent Kosten Effektivitäts Trial.
    Jeger RV; Brunner-La Rocca HP; Hunziker PR; Tsakiris DA; Kaiser CA; Pfisterer ME;
    Clin Ther; 2009 Dec; 31(12):2886-93. PubMed ID: 20110027
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Perioperative Antiplatelet Bridging With Cangrelor: A Cohort Study and Narrative Review.
    Salgia A; Krueger CK; Gillette MA
    Ann Pharmacother; 2023 May; 57(5):544-552. PubMed ID: 36004393
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
    Hahn JY; Song YB; Choi JH; Choi SH; Lee SY; Park HS; Hur SH; Lee S; Han KR; Rha SW; Cho BR; Park JS; Yoon J; Lim DS; Lee SH; Gwon HC;
    Circ J; 2010 Nov; 74(11):2314-21. PubMed ID: 20938098
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Coronary stent management in elective genitourinary surgery.
    Gupta AD; Streiff M; Resar J; Schoenberg M
    BJU Int; 2012 Aug; 110(4):480-4. PubMed ID: 22192977
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Outcomes of a preoperative "bridging" strategy with glycoprotein IIb/IIIa inhibitors to prevent perioperative stent thrombosis in patients with drug-eluting stents who undergo surgery necessitating interruption of thienopyridine administration.
    Alshawabkeh LI; Prasad A; Lenkovsky F; Makary LF; Kandil ES; Weideman RA; Kelly KC; Rangan BV; Banerjee S; Brilakis ES
    EuroIntervention; 2013 Jun; 9(2):204-11. PubMed ID: 23454910
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Bridging therapy after recent stent implantation: case report and review of data.
    Wessler JD; Saldana F; Giugliano RP
    Cardiovasc Revasc Med; 2012; 13(1):30-8. PubMed ID: 22019210
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Randomized Comparison of Oral P2Y
    Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
    JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Case report: reuse of tirofiban leads to very severe thrombocytopenia.
    Li Y; Qiu J; Gao Y; Li G
    Front Cardiovasc Med; 2023; 10():1130552. PubMed ID: 37273872
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Deciphering dual antiplatelet therapy in the era of drug-eluting coronary stents.
    Bell B; Walters D; Spaulding C
    Curr Drug Targets; 2009 Jun; 10(6):519-29. PubMed ID: 19519354
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Severe thrombocytopenia induced by tirofiban after percutaneous coronary intervention: a case report.
    Wang ZM; Wang B; Li YF; Chen B; Shen Q; Li DF; Wang LS
    J Med Case Rep; 2023 Oct; 17(1):430. PubMed ID: 37838704
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
    Dorsch MP; Montague D; Rodgers JE; Patterson C
    Pharmacotherapy; 2006 Mar; 26(3):423-7. PubMed ID: 16503724
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM
    Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
    Stone GW; Moliterno DJ; Bertrand M; Neumann FJ; Herrmann HC; Powers ER; Grines CL; Moses JW; Cohen DJ; Cohen EA; Cohen M; Wolski K; DiBattiste PM; Topol EJ
    Circulation; 2002 May; 105(20):2347-54. PubMed ID: 12021219
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety and Efficacy of Periprocedural Bridging With Cangrelor Versus Eptifibatide.
    Yun AN; Toyoda AY; Solomon EJ; Roberts RJ; Ji CS
    J Cardiovasc Pharmacol; 2022 Mar; 79(3):383-389. PubMed ID: 35255052
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.